ACIU - ACイミュ―ン （AC Immune SA） ACイミュ―ンACIUのチャート
ACIUの企業情報
| symbol | ACIU |
|---|---|
| 会社名 | AC Immune SA （ACイミュ―ン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases such as Down syndrome glaucoma and Parkinson''s and focuses on producing therapeutic and diagnostic product candidates using SupraAntigen and Morphomer technology platforms. The Company''s pipeline includes Crenezumab ACI-24 Anti-Tau antibody Morphomer Tau Tau-PET imaging agent Morphomer Abeta and Morphomer alpha-syn among others. ACイミュ―ンはスイスのバイオ医薬品企業。臨床段階で、細胞内のタンパク質の折りたたみ異常に起因する神経変性疾患の特定や治療薬の開発に従事する。広範囲の神経変性疾患を対象にパ―キンソン病、ダウン症、緑内障の予防や診断、治療に対応するために抗体や小分子、ワクチンを作成する。本社はラウサネ。 AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen. |
| 本社所在地 | EPFL Innovation Park Building B Lausanne 1015 CHE |
| 代表者氏名 | Martin Velasco マーティンベラスコ |
| 代表者役職名 | Chairman of the Board of Directors |
| 電話番号 | +41 21-345-9121 |
| 設立年月日 | 37653 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.acimmune.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aciu |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.79702 |
| 終値（lastsale） | 7.35 |
| 時価総額（marketcap） | 495115771.5 |
| 時価総額 | 時価総額（百万ドル） 527.14420 |
| 売上高 | 売上高（百万ドル） 21.15660 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 424.17964 |
| 当期純利益 | 当期純利益（百万ドル） -27.61319 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AC Immune SA revenues increased 26% to SF3.5M. Net loss increased 4% to SF22.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Operating Expense - R&D increase of 57% to SF15.2M (expense) Labor_Related Expenses in R&D increase from SF2.2M to SF5.4M (expense). |
ACIUのテクニカル分析
ACIUのニュース
Can you now get a good deal on AC Immune SA’s shares? 2023/02/09 15:24:00 US Post News
A share of AC Immune SA (NASDAQ:ACIU) closed at $2.38 per share on Wednesday, down from $2.42 day before. While AC Immune SA has underperformed by -1.65%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACIU fell by -49.15%, with highs and lows ranging from $4.84 […]
AC Immune SA: AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 2023/02/07 12:10:00 Finanz Nachrichten
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune''s first-in-class TDP-43 PET trac…
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 2023/02/07 12:00:00 GlobeNewswire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
AC Immune SA: AC Immune to Present at the SVB Securities Global Biopharma Conference 2023/02/02 13:22:00 Finanz Nachrichten
AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023 - AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering p…
AC Immune to Present at the SVB Securities Global Biopharma 2023/02/02 13:15:00 businessfortnight.com
AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for […] The post AC Immune to Present at the SVB Securities Global Biopharma appeared first on Businessfortnight .
How should investors view AC Immune SA (ACIU)? 2023/01/06 14:54:00 US Post News
AC Immune SA (NASDAQ:ACIU) marked $2.13 per share on Thursday, down from a previous closing price of $2.18. While AC Immune SA has underperformed by -2.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACIU fell by -57.65%, with highs and lows ranging from $5.12 to […]
A Full Position In AC Immune To My Tax Loss Selling Basket (ACIU) 2022/12/27 18:02:46 Seeking Alpha
AC Immune recently fell due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand. Read why I have a full position in ACIU.
Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock? 2022/12/22 16:00:00 Marketing Sentinel
AC Immune SA (NASDAQ:ACIU)’s traded shares stood at 1.88 million during the last session, with the company’s beta value hitting 0.56. At the close of trading, the stock’s price was $1.79, to imply an increase of 2.87% or $0.05 in intraday trading. The ACIU share’s 52-week high remains $5.40, putting it -201.68% down since that … Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock? Read More »
AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead 2022/12/17 13:30:00 Marketing Sentinel
In last trading session, AC Immune SA (NASDAQ:ACIU) saw 0.61 million shares changing hands with its beta currently measuring 0.52. Company’s recent per share price level of $1.94 trading at -$0.1 or -4.90% at ring of the bell on the day assigns it a market valuation of $161.41M. That closing price of ACIU’s stock is … AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead Read More »
AC Immune Could Reload On Upcoming Readout 2022/12/06 12:42:34 Seeking Alpha
AC Immune has a lot of cash. Their lead vaccine was selected by a Big Pharma partner for later-stage development. See our analysis of ACIU stock here.
A Full Position In AC Immune To My Tax Loss Selling Basket (ACIU) 2022/12/27 18:02:46 Seeking Alpha
AC Immune recently fell due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand. Read why I have a full position in ACIU.
Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock? 2022/12/22 16:00:00 Marketing Sentinel
AC Immune SA (NASDAQ:ACIU)’s traded shares stood at 1.88 million during the last session, with the company’s beta value hitting 0.56. At the close of trading, the stock’s price was $1.79, to imply an increase of 2.87% or $0.05 in intraday trading. The ACIU share’s 52-week high remains $5.40, putting it -201.68% down since that … Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock? Read More »
AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead 2022/12/17 13:30:00 Marketing Sentinel
In last trading session, AC Immune SA (NASDAQ:ACIU) saw 0.61 million shares changing hands with its beta currently measuring 0.52. Company’s recent per share price level of $1.94 trading at -$0.1 or -4.90% at ring of the bell on the day assigns it a market valuation of $161.41M. That closing price of ACIU’s stock is … AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead Read More »
AC Immune Could Reload On Upcoming Readout 2022/12/06 12:42:34 Seeking Alpha
AC Immune has a lot of cash. Their lead vaccine was selected by a Big Pharma partner for later-stage development. See our analysis of ACIU stock here.
AC Immune SA: AC Immune''s Alzheimer''s Disease Vaccine-candidate ACI-35.030 Selected for Further Development 2022/11/30 12:05:00 Finanz Nachrichten
AC Immune''s Alzheimer''s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased…